Delving into the Latest Updates on Danicopan with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ACH-CFDIS, Danicopan (JAN/USAN/INN), ACH-0144471

+ [4]

Target

CFD

Mechanism

CFD inhibitors(Complement factor D inhibitors)

Therapeutic Areas

Hemic and Lymphatic DiseasesOther DiseasesCongenital Disorders+ [1]

Active Indication

Hemoglobinuria, ParoxysmalHemolysisAge Related Macular Degeneration+ [1]

Inactive Indication

C3 glomerulopathyCOVID-19Glomerulonephritis, Membranoproliferative+ [3]

Originator Organization

Alexion Pharmaceuticals, Inc.

Active Organization

Alexion Pharmaceuticals, Inc.AstraZeneca Korea Ltd.Alexion Europe SAS

Inactive Organization

Achillion Pharmaceuticals, Inc.National Institute of Allergy & Infectious Diseases

Drug Highest PhaseApproved

First Approval Date

JP (18 Jan 2024),

Hemoglobinuria, Paroxysmal

RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (EU), PRIME (EU), Orphan Drug (JP), Paediatric investigation plan (EU)

Login to view First Approval Timeline

Structure

Molecular FormulaC26H23BrFN7O3

InChIKeyPIBARDGJJAGJAJ-NQIIRXRSSA-N

CAS Registry1903768-17-1

The primary objective of this study is to evaluate efficacy of danicopan as add-on treatment to ravulizumab or eculizumab as assessed by hemoglobin (Hgb) change from Baseline at Week 12 in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH) and clinically significant extravascular hemolysis (CS-EVH).

Start Date23 Aug 2024

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

NCT05708573 / CompletedPhase 1

A Phase 1 Study to Evaluate the Potential Drug Interaction Between ALXN2040 and Rosuvastatin in Healthy Adult Participants

This study will assess the potential drug-drug interaction (DDI) between ALXN2040 and rosuvastatin.

Start Date01 Feb 2023

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

NCT05389449 / Active, not recruitingPhase 3

A Long-term Extension (LTE) Study to Characterize the Safety and Efficacy of Danicopan as an Add-on Therapy to a Complement Component 5 Inhibitor (C5i) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Previously Treated With Danicopan in an Alexion-sponsored Clinical Study

This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.

Start Date28 Oct 2022

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

100 Clinical Results associated with Danicopan

Login to view more data

100 Translational Medicine associated with Danicopan

Login to view more data

100 Patents (Medical) associated with Danicopan

Login to view more data

1,442

Literatures (Medical) associated with Danicopan

01 Dec 2023·Human & experimental toxicology

Prenatal cyanuric acid exposure induced spatial learning impairments associated with alteration of acetylcholine-mediated neural information flow at the hippocampal CA3-CA1 synapses of male rats

Article

Author: Li, Xiaoliang ; Wan, Yiwen ; Mei, Yazi ; Zhao, Xuanyin ; Yang, Yang ; Chen, Xiao ; Sun, Wei ; An, Lei

Cyanuric acid (CA) is reported to induce nephrotoxicity but its toxic effect is not fully known. Prenatal CA exposure causes neurodevelopmental deficits and abnormal behavior in spatial learning ability. Dysfunction of the acetyl-cholinergic system in neural information processing is correlated with spatial learning impairment and was found in the previous reports of CA structural analogue melamine. To further investigate the neurotoxic effects and the potential mechanism, the acetylcholine (ACh) level was detected in the rats which were exposed to CA during the whole of gestation. Local field potentials (LFPs) were recorded when rats infused with ACh or cholinergic receptor agonist into hippocampal CA3 or CA1 region were trained in the Y-maze task. We found the expression of ACh in the hippocampus was significantly reduced in dose-dependent manners. Intra-hippocampal infusion of ACh into the CA1 but not the CA3 region could effectively mitigate learning deficits induced by CA exposure. However, activation of cholinergic receptors did not rescue the learning impairments. In the LFP recording, we found that the hippocampal ACh infusions could enhance the values of phase synchronization between CA3 and CA1 regions in theta and alpha oscillations. Meanwhile, the reduction in the coupling directional index and the strength of CA3 driving CA1 in the CA-treated groups was also reversed by the ACh infusions. Our findings are consistent with the hypothesis and provide the first evidence that prenatal CA exposure induced spatial learning defect is attributed to the weakened ACh-mediated neuronal coupling and NIF in the CA3-CA1 pathway.

01 Dec 2023·The Lancet. Haematology

Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial

Article

Author: Rojnuckarin, Ponlapat ; Gutierrez, Emilio Ojeda ; Kim, Jeong-A ; de la Tour, Régis Peffault ; Forcade, Edouard ; Griffin, Morag ; Capra, Marcelo ; Mitchell, Lindsay ; Patriquin, Christopher ; Shammo, Jamile ; Barcellini, Wilma ; Gonzalez-Fernandez, Ataulfo ; Risitano, Antonio ; Kosugi, Hiroshi ; Nishimura, Jun-ichi ; Ishida, Tadao ; Obara, Naoshi ; Samuel, Desmond ; Chew, Lee Ping ; Jang, Jun Ho ; Iori, Anna Paola ; Di Bona, Eros ; De Oliveira, Michel Michels ; Kitano, Toshiyuki ; Fu, Chieh-Lin ; Jain, Deepak ; Lee, Jong Wook ; Piekarska, Agnieszka ; Ibrahim, Ibrahim ; Lee Lee, Lily Wong ; Notaro, Rosario ; Sicre de Fontbrune, Flore ; Giannouli, Stavroula ; Uchiyama, Hitoji ; Yamaguchi, Hiroki ; Pessoa, Viviani ; Takami, Akiyoshi ; Piatek, Caroline ; Kulasekararaj, Austin ; Oliva, Esther Natalie ; Hernández-Rodríguez, Inés ; Chrysavgi, Lalayanni ; Vannucchi, Alessandro Maria ; Furha, Cossor ; Beneitez Pastor, David ; Carrillo Infante, Cynthia ; De Castro, Carlos ; Filippov, Gleb ; Nunez, Ramiro ; Kulasekararaj, Austin G ; Tadmor, Tamar ; Raza, Shahzad ; Barraco, Fiorenza ; Nishiwaki, Kaichi ; Terriou, Louis ; Tamari, Roni ; Risitano, Antonio Maria ; Gaya Valls, Anna ; Mori, Yasuo ; Liu, Peng ; Kim, Jin Seok ; Gural, Alexander ; Mayer, Jiri ; Kreiniz, Natalia

BACKGROUND:

Symptoms of anaemia due to clinically significant extravascular haemolysis can affect patients with paroxysmal nocturnal haemoglobinuria (PNH) treated with C5 inhibitors (ravulizumab or eculizumab). The aim of this study was to assess the efficacy and safety of danicopan (ALXN2040), an investigational, first-in-class, oral complement factor D inhibitor, as add-on therapy to ravulizumab or eculizumab in patients with PNH and clinically significant extravascular haemolysis.

METHODS:

ALPHA is an ongoing, international, phase 3, randomised, double-blind, placebo-controlled trial evaluating danicopan as add-on therapy to ravulizumab or eculizumab. Eligible patients were adults (age ≥18 years) with PNH and clinically significant extravascular haemolysis (haemoglobin ≤9·5 g/dL; absolute reticulocyte count ≥120 × 10⁹/L) on ravulizumab or eculizumab for at least 6 months. Patients were randomly assigned (2:1) to danicopan or placebo added to ravulizumab or eculizumab for 12 weeks using an interactive response technology system. Randomisation was stratified based on transfusion history, haemoglobin, and patients enrolled from Japan. The initial oral danicopan dose was 150 mg three times a day; escalation to 200 mg three times a day was permitted based on clinical response. The infusion dose level of eculizumab (every 2 weeks) ranged from 900 mg to 1500 mg, and for ravulizumab (monthly or every 8 weeks) ranged from 3000 mg to 3600 mg. The primary endpoint was change in haemoglobin concentration from baseline to week 12. Here we present the protocol-prespecified interim analysis, planned when approximately 75% of participants were randomly assigned to treatment and completed or discontinued at 12 weeks. This trial is registered with ClinicalTrials.gov (NCT04469465).

FINDINGS:

Individuals were randomly assigned between Dec 16, 2020, and Aug 29, 2022. At data cutoff (June 28, 2022), 73 individuals were randomly assigned, received treatment, and were analysed for safety (danicopan, n=49; placebo, n=24). The protocol-prespecified interim efficacy analysis set included the first 63 participants (danicopan, n=42; placebo, n=21). At week 12, danicopan plus ravulizumab or eculizumab increased haemoglobin versus placebo plus ravulizumab or eculizumab (least squares mean [LSM] change from baseline: danicopan, 2·94 g/dL [95% CI 2·52 to 3·36]; placebo, 0·50 g/dL [-0·13 to 1·12]; LSM difference, 2·44 g/dL [1·69 to 3·20]; p<0·0001). Grade 3 adverse events in the danicopan group were increased alanine aminotransferase (two [4%] of 49 patients), leukopenia (one [2%]), neutropenia (two [4%]), cholecystitis (one [2%]), COVID-19 (one [2%]), increased aspartate aminotransferase (one [2%]), and increased blood pressure (one [2%]), and in the placebo group were anaemia (one [4%] of 24 patients), thrombocytopenia (one [4%]), and asthenia (one [4%]). The serious adverse events reported in the danicopan group were cholecystitis (one [2%] patient) and COVID-19 (one [2%]) and in the placebo group were anaemia and abdominal pain, both in one (4%) patient. There were no serious adverse events related to study drug or deaths reported in the study.

INTERPRETATION:

These primary efficacy and safety results show that danicopan as add-on treatment to ravulizumab or eculizumab significantly improved haemoglobin concentrations at week 12 with no new safety concerns, suggesting an improved benefit-risk profile in patients with PNH and clinically significant extravascular haemolysis.

FUNDING:

Alexion, AstraZeneca Rare Disease.

01 May 2023·American journal of therapeutics

Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria.

Article

Author: Malieckal, Deepa A ; Khan, Nida ; Boisclair, Stephanie ; Begum, Farhana ; Chitty, David

BACKGROUND:

Complement-mediated HUS (CM-HUS) and paroxysmal nocturnal hemoglobinuria (PNH) are rare hematologic disorders that cause dysregulation and hyperactivation of the complement system. Historically, treatment of CM-HUS involved plasma exchange (PLEX), often with limited benefit and variable tolerance. Conversely, PNH was treated with supportive care or hemopoietic stem cell transplant. Within the last decade, monoclonal antibody therapies that block terminal complement pathway activation, have emerged as less invasive and more efficacious options for management of both disorders. This manuscript seeks to discuss a relevant clinical case of CM-HUS and the evolving landscape of complement inhibitor therapies for CM-HUS and PNH.

AREAS OF UNCERTAINTY:

Eculizumab, the first humanized anti-C5 monoclonal antibody, has been the standard of care in treating CM-HUS and PNH for over a decade. Although eculizumab has remained an effective agent, the variability in ease and frequency of administration has remained an obstacle for patients. The development of novel complement inhibitor therapies with longer half-lives, has allowed for changes in frequency and route of administration, thus improving patient QOL. However, there are limited prospective clinical trial data given disease rarity, and limited information on variable infusion frequency and length of treatment.

THERAPEUTIC ADVANCES:

Recently, there has been a push to formulate complement inhibitors that improve QOL while maintaining efficacy. Ravulizumab, a derivative of eculizumab, was developed to allow for less frequent administration, while remaining efficacious. In addition, the novel oral and subcutaneous therapies, danicopan and crovalimab, respectively, along with pegcetacoplan are currently undergoing active clinical trials, and poised to further reduce treatment burden.

CONCLUSION:

Complement inhibitor therapies have changed the treatment landscape for CM-HUS and PNH. With a significant emphasis on patient QOL, novel therapies continue to emerge and require an in-depth review of their appropriate use and efficacy in these rare disorders.

CLINICAL CASE:

A 47-year-old woman with hypertension and hyperlipidemia presented with shortness of breath and was found to have hypertensive emergency in the setting of acute renal failure. Her serum creatinine was 13.9 mg/dL; elevated from 1.43 mg/dL 2 years before. The differential diagnosis for her acute kidney injury (AKI) included infectious, autoimmune, and hematologic processes. Infectious work-up was negative. ADAMTS13 activity level was not low at 72.9%, ruling out thrombotic thrombocytopenic purpura (TTP). Patient underwent a renal biopsy, which revealed acute on chronic thrombotic microangiopathy (TMA). A trial of eculizumab was initiated with concurrent hemodialysis. The diagnosis of CM-HUS was later confirmed by a heterozygous mutation in complement factor I (CFI), resulting in increased membrane attack complex (MAC) cascade activation. The patient was maintained on biweekly eculizumab and was eventually transitioned to ravulizumab infusions as an outpatient. Her renal failure did not recover, and the patient remains on hemodialysis while awaiting kidney transplantation.

34

News (Medical) associated with Danicopan

29 May 2024

·www.pharmamanufacturing.com

FDA approves Amgen rare disease biosim

The U.S. FDA approved Amgen's Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca's Soliris (eculizumab) for treating two rare diseases. Bkemv is now approved for reducing hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) and inhibiting complement-mediated thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome (aHUS). The approvals align with the indications currently approved for Soliris, which was first approved in 2007 . PNH and aHUS are characterized by the breakdown of red blood cells. PNH results in anemia, blood clots, low blood cell counts, and dark urine, while aHUS results in anemia, low platelets, and kidney failure. Bkemv, a monoclonal antibody, binds to the complement C5 protein, inhibiting the complement system and preventing the breakdown of red blood cells in PNH and aHUS patients. Bkemv is the 53rd approved biosimilar in the U.S., with 13 approved as interchangeable biosimilars. An interchangeable biosimilar can be substituted for the reference product without consulting the prescriber, subject to state pharmacy laws, similar to generic drug substitution for brand-name drugs. Recently, the FDA also approved AstraZeneca's voydeya as an add-on to the standard-of-care — Ultomiris or Soliris — to address the needs of the approximately 10-20% of patients with PNH who experienced clinically significant extravascular hemolysis (EVH) while treated with a C5 inhibitor. For some patients, EVH, which is the destruction of red blood cells outside of the blood vessels, resulted in continued symptoms of anemia and may require blood transfusions.

Drug ApprovalBiosimilar

23 Apr 2024

·firstwordpharma.com

EU okays AstraZeneca’s factor D inhibitor Voydeya for rare blood disorder

The European Commission approved AstraZeneca’s Voydeya (danicopan) as an add-on treatment for adults with paroxysmal nocturnal haemoglobinuria (PNH) receiving C5 inhibitor therapies Ultomiris (ravulizumab) or Soliris (eculizumab). The drugmaker noted Tuesday that the factor D inhibitor specifically addresses significant extravascular haemolysis (EVH), a phenomenon seen in around 10% to 20% of C5 inhibitor recipients.Hot on the heels of recent Japanese and US approvals, the decision follows a positive stance adopted by the European Medicines Agency's (EMA) drug advisory body in February. “We look forward to making this first-in-class factor D inhibitor available to patients in Europe and to advancing access around the globe,” remarked Marc Dunoyer, CEO of the company’s rare disease unit Alexion.The EU approval was based on positive findings from the Phase III ALPHA study, which investigated add-on Voydeya in Ultomiris- or Soliris-treated patients with PNH and clinically significant EVH. Results showed that Voydeya met the primary endpoint of change in haemoglobin from baseline to week 12, alongside all key secondary goals. Moreover, the therapy was well tolerated, with no new safety signals observed.Another drug on the brink of EU approval in PNH is Novartis' factor B inhibitor Fabhalta (iptacopan), which recently secured a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.

Clinical ResultPhase 3Drug Approval

08 Apr 2024

·www.globenewswire.com

Onco360 Has Been Selected as the Sole National Specialty Pharmacy Partner for Voydeya® (danicopan)

LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for Voydeya® (Danicopan) as a first class oral, Factor D inhibitor. It is FDA-approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in combination with C5 inhibitor, Ultomiris® (Ravulizumab) or Soliris® (Eculizumab) for patients that experience clinically significant extravascular hemolysis (EVH).1 Voydeya® is an oral, Factor D inhibitor that acts in the alternative complement pathway of the immune system, providing control of red blood cell destruction within and outside the blood vessels. “Onco360 appreciates the opportunity to partner further with the team at Alexion and become the sole national specialty pharmacy provider for Voydeya®”, said Benito Fernandez, Chief Commercial Officer. “We are proud to add this first in class oral Factor D inhibitor treatment option for PNH patients.” For more information please see Alexion Press Release. About Onco360 Oncology Pharmacy:Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com. Please see the full Prescribing Information for Voydeya® Media Contact: Benito Fernandez, Chief Commercial OfficerBenito.Fernandez@Onco360.com516-640-1332 Reference: Voydeya Prescribing Information. Boston, MA: Alexion Pharmaceutical Corp; March 2024.

Drug ApprovalBiosimilar

100 Deals associated with Danicopan

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11641	-	-	DB15401

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hemoglobinuria, Paroxysmal	JP	Alexion Pharmaceuticals, Inc.	18 Jan 2024

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemolysis	Phase 3	-	Alexion Pharmaceuticals, Inc.	23 Aug 2024
Age Related Macular Degeneration	Phase 2	US	Alexion Pharmaceuticals, Inc.	23 Aug 2021
Age Related Macular Degeneration	Phase 2	JP	Alexion Pharmaceuticals, Inc.	23 Aug 2021
Age Related Macular Degeneration	Phase 2	AU	Alexion Pharmaceuticals, Inc.	23 Aug 2021
Age Related Macular Degeneration	Phase 2	CA	Alexion Pharmaceuticals, Inc.	23 Aug 2021
Age Related Macular Degeneration	Phase 2	CZ	Alexion Pharmaceuticals, Inc.	23 Aug 2021
Age Related Macular Degeneration	Phase 2	FR	Alexion Pharmaceuticals, Inc.	23 Aug 2021
Age Related Macular Degeneration	Phase 2	DE	Alexion Pharmaceuticals, Inc.	23 Aug 2021
Age Related Macular Degeneration	Phase 2	HU	Alexion Pharmaceuticals, Inc.	23 Aug 2021
Age Related Macular Degeneration	Phase 2	IT	Alexion Pharmaceuticals, Inc.	23 Aug 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04469465 (ALPHA, EHA2024) Manual	Phase 3	Hemoglobinuria, Paroxysmal	86	Danicopan + Ravulizumab/Eculizumab	mwjplnidjp(fkdwmnaedj) = The proportion of pts with increased Hb (≥2 g/dL) without transfusion was maintained in the Dan–Dan arm and improved in the Pbo–Dan arm from wk 12 to 24 (Dan–Dan, 54.4% to 41.8%; Pbo–Dan, 0% to 33.3%). At wks 24 and 48, mean Hb levels and ARC were maintained in the Dan–Dan arm andimproved from wk 12 in the Pbo–Dan arm deeynikiws (ieholbrqsx ) View more	Positive	14 May 2024
NCT04469465 (ALXN2040-PNH-301, FDA_CDER) Manual	Phase 3	Hemoglobinuria, Paroxysmal	86	VOYDEYA + ravulizumab or eculizumab	mpztreitnd(xevkhgnypv) = uubpxdfxen fuvsggxyym (lxshjiexai ) View more	Positive	30 Mar 2024
				Placebo + ravulizumab or eculizumab	mpztreitnd(xevkhgnypv) = awqehqkdfj fuvsggxyym (lxshjiexai ) View more
ALPHA (BusinessWire) Manual	Phase 3	Hemoglobinuria, Paroxysmal	86	Danicopan + ULTOMIRIS or SOLIRIS (Danicopan-Danicopan)	uwlwexaqgj(wcypkdwpoq) = ikzfywxnqx flvawgksim (radwrrsgzt, 0.21) View more	Positive	10 Dec 2023
				Placebo + ULTOMIRIS or SOLIRIS (placebo-danicopan)	uwlwexaqgj(wcypkdwpoq) = suujxbxhbb flvawgksim (radwrrsgzt, 0.31) View more
NCT04469465 (ALXN2040-PNH-301 \| ALPHA, CTgov)	Phase 3	Hemoglobinuria, Paroxysmal	86	danicopan+eculizumab+ravulizumab (Danicopan)	jcolsjrjnn(uhrfzsxgqg) = ybgnwgcomn psmbvxcvqq (zqqstvsmyp, tjuglgqupz - xhhpkyotuw) View more	-	24 Jul 2023
				placebo+eculizumab+ravulizumab (Placebo)	jcolsjrjnn(uhrfzsxgqg) = ctxmjuusfz psmbvxcvqq (zqqstvsmyp, dpcfagscgx - tujsphqvpa) View more
NCT04988035 (CTgov)	Phase 2	COVID-19	201	Danicopan+Remdesivir (Remdesivir + Danicopan)	mbwrhuqmeb(jokhgpkfrf): Odds Ratio (OR) = 0.64 (95% CI, 0.38 - 1.07), P-Value = 0.090 View more	-	08 Jun 2023
				Placebo+Remdesivir (Remdesivir + Placebo)
NCT03181633 (CTgov)	Phase 2	Hemoglobinuria, Paroxysmal	8	danicopan	glmwdbrbtm(huqrmneoao) = dlxiumsjcx jiodamlolb (zqeewhcktu, lahmtzffde - jrjuyglpie) View more	-	14 Mar 2023
NCT03459443 (CTgov)	Phase 2	Glomerulonephritis, Membranoproliferative \| C3 glomerulopathy	22	Danicopan	cnwypfojlq(emtorprksq) = fqhawvcscz acfbqifzuk (wmnuagsvsi, uvsrbjxrlv - lpjbtgjfxw) View more	-	11 Aug 2022
NCT03472885 (Pubmed) Manual	Phase 2	Hemoglobinuria, Paroxysmal	12	Danicopan	xsvdhtoykv(ezpnzonatc) = dasbhnaubm sqcohbkjim (pjbgtsqojv ) View more	Positive	18 Nov 2021
NCT03369236 (CTgov)	Phase 2	Glomerulonephritis, Membranoproliferative \| C3 glomerulopathy	13	Placebo+Danicopan (Placebo (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period))	augixhodhd(esqeomklgt) = ibwjljprie duxtnjootd (cetbpjfofm, rubosntrug - kfzfqyxknk) View more	-	04 Nov 2021
				Danicopan (Danicopan (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period))	cvfysdufxb(ihfykcnmeo) = yuwjpqnytg aqhgopfhsh (pasdxjeqkg, byexhetpss - tuafacyxgt)
NCT03124368 (CTgov)	Phase 2	Glomerulonephritis, Membranoproliferative \| C3 glomerulopathy	6	Danicopan (Group 1: Danicopan 100 mg TID (Sentinel))	jbivreppxe(ltjsfvwwan) = alrpbzgkjm eigzkuphek (tpmecgkuqk, itrprnuhxl - kcrdevooky) View more	-	13 Jul 2021
				Danicopan (Group 2: Danicopan up to 200 mg TID)	jbivreppxe(ltjsfvwwan) = hljfnaoruu eigzkuphek (tpmecgkuqk, qgplztpynt - jpilypfoxy) View more